KLRS
$8.52
Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its n...
Recent News
We Think Kalaris Therapeutics (NASDAQ:KLRS) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Kalaris Therapeutics, Inc.'s (NASDAQ:KLRS) biggest owners are private equity firms who got richer after stock soared 24% last week
Key Insights Kalaris Therapeutics' significant private equity firms ownership suggests that the key decisions are...
Kalaris Therapeutics Inc. (KLRS) Upgraded to Buy: Here's What You Should Know
Kalaris Therapeutics Inc. (KLRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
We're Hopeful That Kalaris Therapeutics (NASDAQ:KLRS) Will Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, although...